Methodological challenges in assessing the impact of comorbidities on costs in Alzheimer's disease clinical trials
Year of publication: |
December 2015
|
---|---|
Authors: | Kahle-Wrobleski, Kristin ; Fillit, Howard ; Kurlander, Jonathan ; Reed, Catherine ; Belger, Mark |
Published in: |
The European journal of health economics : HEPAC ; health economics in prevention and care. - Berlin : Springer, ISSN 1618-7598, ZDB-ID 2045253-6. - Vol. 16.2015, 9, p. 995-1004
|
Subject: | Alzheimer's disease | Randomized controlled trials | Semagacestat | Comorbidities | Concomitant medications | Economics | Kosten | Costs | Krankheit | Disease |
-
Social and family load of Alzheimer's disease
Maresova, Petra, (2016)
-
Die Kosten der Heparininduzierten Thrombozytopenie (HIT-II) : eine pharmakoökonomische Analyse
Tesch, Stefan, (2009)
-
Modellierung der Lebenszeitkosten der Karies unter Einfluss von Fluoridprophylaxe
Fleßa, Steffen, (2007)
- More ...
-
Belger, Mark, (2019)
-
Multilevel network meta‐regression for population‐adjusted treatment comparisons
Phillippo, David M., (2020)
-
Hill, Jerrold, (2006)
- More ...